ATE520406T1 - Kristalline form des ibandronat-natriums - Google Patents

Kristalline form des ibandronat-natriums

Info

Publication number
ATE520406T1
ATE520406T1 AT08002626T AT08002626T ATE520406T1 AT E520406 T1 ATE520406 T1 AT E520406T1 AT 08002626 T AT08002626 T AT 08002626T AT 08002626 T AT08002626 T AT 08002626T AT E520406 T1 ATE520406 T1 AT E520406T1
Authority
AT
Austria
Prior art keywords
ibandronate sodium
crystalline form
ray
crystalline
sodium
Prior art date
Application number
AT08002626T
Other languages
English (en)
Inventor
Revital Lifshitz-Liron
Thomas Bayer
Judith Aronhime
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35968334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE520406(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE520406T1 publication Critical patent/ATE520406T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
AT08002626T 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums ATE520406T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60402604P 2004-08-23 2004-08-23
US69086705P 2005-06-16 2005-06-16

Publications (1)

Publication Number Publication Date
ATE520406T1 true ATE520406T1 (de) 2011-09-15

Family

ID=35968334

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08002626T ATE520406T1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums
AT05791142T ATE495747T1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums und herstellungsverfahren dafür

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05791142T ATE495747T1 (de) 2004-08-23 2005-08-23 Kristalline form des ibandronat-natriums und herstellungsverfahren dafür

Country Status (12)

Country Link
US (1) US7563918B2 (de)
EP (2) EP1930011B1 (de)
JP (1) JP4559431B2 (de)
KR (2) KR20070043043A (de)
CN (1) CN101022812A (de)
AT (2) ATE520406T1 (de)
CA (1) CA2576659A1 (de)
DE (2) DE602005025977D1 (de)
ES (1) ES2358269T3 (de)
IL (1) IL181298A (de)
PT (2) PT1930011E (de)
WO (1) WO2006024024A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5026077B2 (ja) 2003-09-12 2012-09-12 アムジエン・インコーポレーテツド カルシウム受容体−活性化合物の急速溶解処方
LT2662380T (lt) * 2005-02-01 2019-03-12 Atnahs Pharma Uk Limited Ibandronato polimorfo a medicininis panaudojimas
DK1848727T3 (da) * 2005-02-01 2015-07-20 Hoffmann La Roche Ibandronat polymorf b
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
EP2046342A4 (de) * 2006-07-28 2011-05-04 Reddys Lab Ltd Dr Kristalline form a von ibandronsäure und herstellungsverfahren dafür
JP2009516004A (ja) * 2006-11-16 2009-04-16 テバ ファーマシューティカル インダストリーズ リミティド イバンドロン酸ナトリウムの結晶形態
CA2570949A1 (en) 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
EP2144919B1 (de) 2007-04-11 2015-12-02 F. Hoffmann-La Roche AG Mehrstufige synthese von ibandronat
BRPI0810408A2 (pt) 2007-04-19 2014-11-04 Reddys Lab Ltd Dr Polimorfos de ibandronaro de sódio
WO2009020483A1 (en) * 2007-08-09 2009-02-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of ibandronate sodium
EP2128166A1 (de) 2008-05-20 2009-12-02 Chemo Ibérica, S.A. Polymorphe Ibandronat-Natrium-Formen und Verfahren zu ihrer Herstellung
ES2428699T3 (es) * 2007-10-26 2013-11-08 Chemo Ibérica, S.A. Formas polimórficas de ibandronato de sodio y procedimientos para la preparación del mismo
WO2009061336A1 (en) * 2007-11-05 2009-05-14 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium
EP2180003A1 (de) 2008-10-21 2010-04-28 Zentiva, k.s. Herstellung von Trinatriumbandronat
WO2010131267A1 (en) 2009-05-15 2010-11-18 Nox Medical System and methods using flexible capacitive electrodes for measuring biosignals
WO2011016738A1 (en) 2009-08-05 2011-02-10 Zaklady Farmaceutyczne Polpharma Sa A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
MX367937B (es) 2010-01-27 2019-09-12 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos.
US9059532B2 (en) 2010-06-25 2015-06-16 Nox Medical Biometric belt connector
DK2753352T4 (da) 2010-09-03 2022-09-12 Valneva Austria Gmbh Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2013179305A1 (en) * 2012-06-01 2013-12-05 Hetero Research Foundation Ibandronate sodium solid dispersion
WO2014170909A2 (en) 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
WO2015068041A1 (en) 2013-11-06 2015-05-14 Nox Medical Method, apparatus, and system for measuring respiratory effort
PE20160945A1 (es) 2013-11-15 2016-09-26 Akebia Therapeutics Inc Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acetico, composiciones, y usos de las mismas
EP3500155A1 (de) 2016-08-19 2019-06-26 Nox Medical Verfahren, vorrichtung und system zur messung der atemanstrengung einer person
US11896386B2 (en) 2017-06-02 2024-02-13 Nox Medical Ehf Coherence-based method, apparatus, and system for identifying corresponding signals of a physiological study
US11602282B2 (en) 2017-09-08 2023-03-14 Nox Medical Ehf System and method for non-invasively determining an internal component of respiratory effort

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
JP2639721B2 (ja) 1988-12-27 1997-08-13 富士重工業株式会社 内燃機関の燃焼室
US5652227A (en) * 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
DE19637890A1 (de) * 1996-09-17 1998-03-19 Max Planck Gesellschaft Biphosphonat-Liposomen
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
ES2240106T3 (es) * 1999-05-21 2005-10-16 Novartis Ag Uso de acidos bisfosfonicos para el tratamiento de angiogenesis.
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
CN1180846C (zh) * 2000-05-05 2004-12-22 霍夫曼-拉罗奇有限公司 含有双膦酸或其盐的,用于皮下给药的凝胶体状药物组合物
AU7410901A (en) * 2000-06-20 2002-01-02 Novartis Ag Method of administering bisphosphonates
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
MXPA02001219A (es) * 2001-02-01 2005-06-06 Riderway Corp Composicion farmaceutica liquida para el tratamiento de enfermedades oseas.
ITMI20020908A1 (it) 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
KR100642961B1 (ko) * 2002-05-10 2006-11-10 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
MXPA04011337A (es) * 2002-05-17 2005-07-01 Wyeth Corp Portadores de acido hialuronico solidos y susceptibles de ser inyectados para la liberacion de proteinas osteogenicas.
PT1790347E (pt) * 2002-12-20 2015-02-05 Hoffmann La Roche Formulação de ibandronato a dose elevada
EP1716161B1 (de) * 2003-12-23 2011-05-04 Alchymars S.p.A. Amorphe Form das Natriumsalzes der Ibandronsäure
WO2006002348A2 (en) * 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid
LT2662380T (lt) 2005-02-01 2019-03-12 Atnahs Pharma Uk Limited Ibandronato polimorfo a medicininis panaudojimas
DK1848727T3 (da) 2005-02-01 2015-07-20 Hoffmann La Roche Ibandronat polymorf b
WO2007074475A2 (en) 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate

Also Published As

Publication number Publication date
ATE495747T1 (de) 2011-02-15
KR20090120011A (ko) 2009-11-23
JP4559431B2 (ja) 2010-10-06
EP1713489B1 (de) 2011-01-19
ES2358269T3 (es) 2011-05-09
KR20070043043A (ko) 2007-04-24
IL181298A (en) 2011-04-28
EP1930011A3 (de) 2008-06-18
EP1713489A2 (de) 2006-10-25
EP1930011A2 (de) 2008-06-11
WO2006024024A3 (en) 2006-06-29
CA2576659A1 (en) 2006-03-02
US20070179119A1 (en) 2007-08-02
DE602005025977D1 (de) 2011-03-03
WO2006024024A2 (en) 2006-03-02
EP1930011B1 (de) 2011-08-17
PT1930011E (pt) 2011-09-16
JP2007512237A (ja) 2007-05-17
IL181298A0 (en) 2007-07-04
DE202005021414U1 (de) 2008-03-20
CN101022812A (zh) 2007-08-22
PT1713489E (pt) 2011-03-03
US7563918B2 (en) 2009-07-21

Similar Documents

Publication Publication Date Title
ATE520406T1 (de) Kristalline form des ibandronat-natriums
JO2793B1 (en) The new crystalline form 5 of agomelatine, its preparation process and the pharmaceutical ingredients it contains
MY151295A (en) Pyrimidyl indoline compound
MY138941A (en) Aryl-pyridine derivatives
MY147211A (en) Novel dihydropseudoerythromycin derivatives
RS51954B (en) CRYSTAL MODIFICATIONS OF PYRACLOSTROBIN
UA86595C2 (ru) Гамма-кристаллическая форма гидрохлорида ивабрадина, способ ее получения и фармацевтическая композиция, которая ее содержит
JO3360B1 (ar) الشكل البلوري الجديد 3 للأغوميلاتين وعملية تحضيره والمكونات الصيدلانية التي تحتويه
TW200738241A (en) Pyridazine derivatives
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
MY139704A (en) Naphthalene derivatives for use as histamine-3-receptor ligands
UA83718C2 (ru) Кристаллическая форма iv агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
TW200616976A (en) Pyrimidine derivatives
EP1774968A4 (de) Benzylisochinolin-derivat oder bisbenzylisochinolin-derivat enthaltendes psychotropes mittel, analgetikum und/oder antiphlogistikum und nahrungsmittel zur förderung der gesundheit
TW200740764A (en) Pyrazolone derivatives
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
GEP20125433B (en) α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT
MY143557A (en) Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it
HRP20110162A8 (hr) Spojevi koji sadrže amlodipin i bisoprolol
TW200613279A (en) New pesticides
MX2010001705A (es) Co-cristales de pirimetanilo y ditianona.
TW200800993A (en) Organic compounds
TW200738703A (en) 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2007062336A3 (en) Salt forms

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties